Avid Bioservices Inc (CDMO)

[dia76ca]

I found the survival chart "C" on the poster "PS Targeting Antibodies Enhance the Activity of Immune Checkpoint Inhibitors in Tumors" to be most interesting. Could it be that the Bavi/anti-PD-1 combination will be equally or even more effective than the Bavi/Yervoy combination. I look forward to seeing both combinations in the clinic. Here is what was said in the press release.

"Results from these preclinical studies found that animals administered a combination of a PS-targeting antibody and an anti-CTLA-4 or an anti-PD-1 antibody exhibited greater tumor growth suppression and longer survival than anti-CTLA-4 and anti-PD1 antibodies alone. In addition, data showed that animals that survive the initial tumor challenge develop tumor-specific protective immunity and are resistant to re-challenge of the initial tumor. Lastly, tumors from animals treated with PS-targeting in combination with anti-CTLA-4 antibodies show strong and uniform T-cell and macrophage infiltration by immunohistochemical staining."

"These data build on the encouraging data we announced last year showing that the combination of bavituximab and an anti-CTLA-4 antibody yielded enhanced anti-tumor activity in a pre-clinical model of melanoma," said Jeff T. Hutchins, Ph.D. "While this is early data, it is compelling in that the combinations of bavituximab with an anti-CTLA-4 or an anti-PD-1 antibody clearly show both a delay in tumor growth and a decrease in the number of animals with tumor progression. In addition, the discovery of tumor-specific immunity to re-challenge support further investigation into the mechanisms involved and the potential for clinical investigation of these promising upstream and downstream immune checkpoint blockade combinations."